MARKER THERAPEUTICS INC (MRKR) Stock News
NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD
MRKR Latest News, Press Relases and Analysis
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study...
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025...
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9...
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marker Therapeutics (NASDAQ:MRKR) just reported results for the second quarter ...
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024
MRKR stock results show that Marker Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023
Marker Therapeutics just reported results for the fourth quarter of 2023.
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Announces $16.1 Million Private Placement
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T...
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marker Therapeutics (NASDAQ:MRKR) just reported results for the first quarter o...
MRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024
Marker Therapeutics just reported results for the first quarter of 2024.
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete...
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601...
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and...
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study...
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on...
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant...
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical...
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete...
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug...
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy ...